
Injectable, Structural Regenerative Implant for Cartilage Care
Protect • Repair • Regenerate
Cartilage injuries can turn simple movement into a challenge. Without timely treatment, damage may progress and increase the risk of arthritis or future joint replacement.
At Liquid Cartilage, our goal isjoint preservation and regeneration—not replacement. WithChondroFiller®, we deliver advanced, evidence-led care on Harley Street.

Cartilage provides the smooth, low-friction surface that lets your joints move comfortably. It doesn’t readily self-repair, but with the right scaffold and biological cues,regeneration is possible.
Act early to preserve more of what you have.

ChondroFiller® is an acellular,biologic collagen scaffold delivered in liquid form. Once placed, itgels within minutes, filling the defect and providing a framework that invites your cells to rebuild cartilage.
Think of it like “epoxy” for cartilage—without the plastic.
One treatment. One step. A chance to keep your joint for the long term.


ChondroFiller® sits in a different class—structural regenerative implant.
| Treatment | Analogy | What it Does | Limitation |
|---|---|---|---|
| HA (Hyaluronic Acid) | WD-40 | Improves lubrication for short-term comfort | Temporary; does not regenerate tissue |
| Arthrosamid® | Silicone | Acts on the synovium to reduce pain signalling | Not regenerative; literature notes complication rates up to 30% |
| ChondroFiller® | Epoxy resin | Fills defects, stabilises, and promotes true cartilage repair | Most robust injectable option for structural repair |
ChondroFiller®: our structural, regenerative approach to focal cartilage defects.
Small joints: thumb, fingers, elbow, AC joint, toes, TMJ…
From £2,100
Large joints: knee, hip, shoulder, ankle
From £2,800
Best for knee, hip, shoulder
From £6,500 (knee), £9,500 (hip/shoulder)
Our proprietary MSC Co-Delivery Technique
Introductory offer: your consultation fee is credited toward treatment if you proceed.

Quick, no-obligation chat

Comprehensive assessment with Prof. Paul Lee

Injection, Keyhole, or Liquid Cartilage™

Precise and minimally invasive



Cartilage damage won’t reverse on its own—yet with the right plan it can beprotected, repaired, and regenerated.
At Liquid Cartilage, you access world-leading science and a joint-preservation vision on Harley Street.
(Consultation fee credited towards treatment if you proceed.)
Everything you want to know about ChondroFiller® at Liquid Cartilage.
ChondroFiller® is an acellular collagen gel that fills cartilage defects and forms a scaffold for your own cells to regenerate healthy tissue. Unlike temporary injections, it supports hyaline-like restorationfor smoother motion and protection long-term.
HA or Arthrosamid® may give short-term pain relief, while ChondroFiller® aims to rebuild cartilage. Compared with replacement, it preserves your natural joint and avoids prosthesis risks. Our approach is regenerate-first.
Studies show +30 IKDC in knees,+33 Harris Hip Score in hips, and improved ankle metrics. MRI (MOCART) typically reads 70–87. Globally,>19,000 cases support safety and function.
Best for focal defects up to 6 cm² in knees, hips, ankles, or small joints. Active younger patients often benefit, but older patients may qualify if surrounding cartilage is stable.
Delivered via precise injection orkeyhole surgery. The gel sets in minutes. Expectpartial weight-bearing ~6 weeks, steady return to cycling/swimming, and most sports around~12 months alongside specialist rehab.
Harley Street location; UK ICRS Centre of Excellence. Led byProf. Paul Lee, with advanced options likeLiquid Cartilage™ (ChondroFiller® + cells) to prioritise preservation.
Discover what makes ChondroFiller® unique at Liquid Cartilage.

Collagen injected into focal cartilage defects gels into a scaffold that recruits the patient's progenitor cells to rebuild cartilage; widespread joint degeneration is unsuitable.

Talar cartilage lacks direct blood supply and depends on diffusion from bone and synovial fluid for repair. Conservative management requires immobilisation first (4–8 weeks) to allow bone marrow oedema to settle, then physiotherapy. The 3–6 month trial identifies surgical candidates; roughly 45% recover without intervention.

Pain intensity is not the deciding factor for ChondroFiller candidacy; two structural prerequisites apply: documented failure of conservative treatment and MRI-confirmed cartilage damage.

ChondroFiller is an outpatient injection of collagen that gels inside the wrist joint and recruits the patient's own repair cells; a 2025 wrist study showed significantly better cartilage quality in treated joints than controls.

Patients receiving ChondroFiller injection reported functional improvements averaging 32.4 points on the IKDC scale—double the clinically meaningful threshold—with complication rates near zero, though all published evidence derives from manufacturer-sponsored studies and no independent randomised controlled trial exists.

Cartilage damage at the talar dome — the ankle's load-bearing joint surface — occurs in 50–70% of ankle sprains. X-ray misses the injury; MRI reveals it, with lesion size the primary predictor of whether conservative treatment succeeds.